These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 16730032)

  • 1. Reversal learning in Parkinson's disease depends on medication status and outcome valence.
    Cools R; Altamirano L; D'Esposito M
    Neuropsychologia; 2006; 44(10):1663-73. PubMed ID: 16730032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dopamine asymmetry interacts with medication to affect cognition in Parkinson's disease.
    Tomer R; Aharon-Peretz J; Tsitrinbaum Z
    Neuropsychologia; 2007 Jan; 45(2):357-67. PubMed ID: 16876208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of dopamine in cognitive sequence learning: evidence from Parkinson's disease.
    Shohamy D; Myers CE; Grossman S; Sage J; Gluck MA
    Behav Brain Res; 2005 Jan; 156(2):191-9. PubMed ID: 15582105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A dopamine agonist, pramipexole, and cognitive functions in Parkinson's disease.
    Relja M; Klepac N
    J Neurol Sci; 2006 Oct; 248(1-2):251-4. PubMed ID: 16797593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.
    Parkinson Study Group CALM Cohort Investigators
    Arch Neurol; 2009 May; 66(5):563-70. PubMed ID: 19433655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Parkinson's disease duration determines effect of dopaminergic therapy on ventral striatum function.
    MacDonald AA; Monchi O; Seergobin KN; Ganjavi H; Tamjeedi R; MacDonald PA
    Mov Disord; 2013 Feb; 28(2):153-60. PubMed ID: 23165957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopaminergic medication boosts action-effect binding in Parkinson's disease.
    Moore JW; Schneider SA; Schwingenschuh P; Moretto G; Bhatia KP; Haggard P
    Neuropsychologia; 2010 Mar; 48(4):1125-32. PubMed ID: 20018200
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of dopaminergic medications on the time course of explicit motor sequence learning in Parkinson's disease.
    Kwak Y; Müller ML; Bohnen NI; Dayalu P; Seidler RD
    J Neurophysiol; 2010 Feb; 103(2):942-9. PubMed ID: 20018839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Parkinson's disease and dopaminergic medication on proprioceptive processing.
    Mongeon D; Blanchet P; Messier J
    Neuroscience; 2009 Jan; 158(2):426-40. PubMed ID: 18996173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Motor procedural learning in Parkinson's disease.
    Muslimovic D; Post B; Speelman JD; Schmand B
    Brain; 2007 Nov; 130(Pt 11):2887-97. PubMed ID: 17855374
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Basal ganglia, dopamine and temporal processing: performance on three timing tasks on and off medication in Parkinson's disease.
    Jones CR; Malone TJ; Dirnberger G; Edwards M; Jahanshahi M
    Brain Cogn; 2008 Oct; 68(1):30-41. PubMed ID: 18378374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential role of dopamine in emotional attention and memory: evidence from Parkinson's disease.
    Hälbig TD; Assuras S; Creighton J; Borod JC; Tse W; Frisina PG; Voustianiouk A; Gracies JM; Olanow CW
    Mov Disord; 2011 Aug; 26(9):1677-83. PubMed ID: 21638322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dopaminergic influence on disturbed spatial discrimination in Parkinson's disease.
    Shin HW; Kang SY; Sohn YH
    Mov Disord; 2005 Dec; 20(12):1640-3. PubMed ID: 16092109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies.
    Leentjens AF; Koester J; Fruh B; Shephard DT; Barone P; Houben JJ
    Clin Ther; 2009 Jan; 31(1):89-98. PubMed ID: 19243709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopamine and cognitive functioning in de novo subjects with Parkinson's disease: effects of pramipexole and pergolide on working memory.
    Costa A; Peppe A; Dell'Agnello G; Caltagirone C; Carlesimo GA
    Neuropsychologia; 2009 Apr; 47(5):1374-81. PubMed ID: 19428401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of aging, Parkinson's disease, and dopaminergic medication on response selection and control.
    Willemssen R; Falkenstein M; Schwarz M; Müller T; Beste C
    Neurobiol Aging; 2011 Feb; 32(2):327-35. PubMed ID: 19269061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dopaminergic modulation of cognitive interference after pharmacological washout in Parkinson's disease.
    Fera F; Nicoletti G; Cerasa A; Romeo N; Gallo O; Gioia MC; Arabia G; Pugliese P; Zappia M; Quattrone A
    Brain Res Bull; 2007 Sep; 74(1-3):75-83. PubMed ID: 17683792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A dopaminergic basis for working memory, learning and attentional shifting in Parkinsonism.
    Moustafa AA; Sherman SJ; Frank MJ
    Neuropsychologia; 2008 Nov; 46(13):3144-56. PubMed ID: 18687347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are dopaminergic pathways involved in theory of mind? A study in Parkinson's disease.
    Péron J; Vicente S; Leray E; Drapier S; Drapier D; Cohen R; Biseul I; Rouaud T; Le Jeune F; Sauleau P; Vérin M
    Neuropsychologia; 2009 Jan; 47(2):406-14. PubMed ID: 18845171
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Verbal fluency in Parkinson's disease patients on/off dopamine medication.
    Herrera E; Cuetos F; Ribacoba R
    Neuropsychologia; 2012 Dec; 50(14):3636-40. PubMed ID: 22995942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.